Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

June 1, 2013

Chicago, Illinois, USA

Staying a Step Ahead:

Managing Acquired Resistance to EGFR TKI Therapy in NSCLC

An educational symposium held during the 2013 ASCO Annual Meeting. Not an official event of the 2013 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation

Registration

Registration is complimentary with your ASCO Badge.

Available seating will be based on room capacity. Seating is limited and pre-registration does not guarantee admission, as room may be overbooked. Early arrival is recommended and seating will be first come first serve until capacity is met.

Faculty

Mark G. Kris, MD
Memorial Sloan-Kettering Cancer Center
New York, New York

William Pao, MD, PhD
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

Mark A. Socinski, MD
University of Pittsburgh
UPMC Cancer Pavilion
Pittsburgh, Pennsylvania

Agenda

Saturday, June 1, 2013

6:30 pm

Registration and dinner

7:00 pm

Welcome and pre-activity audience polling via ARS
Mark G. Kris, MD, Chair

7:15 pm

Amplification of HER2: New mechanism of resistance and target for therapy
William Pao, MD, PhD

7:35 pm

Question and Answer

7:45 pm

Defining molecular subgroups for MET-targeted therapy: Diagnostics and treatment to maximize benefit
Mark A. Socinski, MD

8:05 pm

Question and Answer

8:15 pm

Next generation of EGFR inhibitors: Improving upon current drugs and strategies
Mark G. Kris, MD

8:35 pm

Question and Answer

8:45 pm

Post-activity audience polling via ARS and faculty panel discussion

8:55 pm

Consensus and recommendations for clinical practice
Mark G. Kris, MD, Chair

9:00 pm

Adjourn

Continuing Medical Education

Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum 2 of AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Who Should Attend

This educational activity is specifically designed for oncologists, pulmonologists, oncology nurses, pharmacists, physician assistants, researchers, and other healthcare professionals involved and/or interested in the therapeutic management of patients with lung cancer and the consequences of this disease.

Objectives

After successful completion of this course, participants should be able to:

  • Identify current and new mechanisms of sensitivity and resistance in NSCLC to EGFR-targeted therapies
  • Describe new therapeutic strategies for sustained response in EGFR-positive NSCLC
  • Enroll patients in clinical trials that use biomarkers for the molecular diagnosis of lung cancer for novel agents or new indications for existing agents

Symposium Location

Michigan Ballroom of the The Westin Michigan Avenue
909 North Michigan Avenue, Chicago, IL 60611
T (312) 943-7200
F (312) 397-5580
www.westin.com/michiganave
Michigan Ballroom

The Symposium Information Desk in the Michigan Ballroom Foyer will be staffed:

Saturday, June 1, 2013 6:00pm-9:00pm

Support

The following company has provided an educational grant in support of this symposium:

Astellas Pharma US, Inc.

Genentech

Organizer

Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Twitter: twitter.com/ImedexCME
Facebook: facebook.com/Imedex
Web: www.imedex.com